The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123
LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq:JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain.
Read more at prnewswire.com